Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

U.S. shares held steady after European equities hit a record high, and gold prices were near an all-time peak as investor ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug ...

US stock futures fell on Wednesday after disappointing earnings from Alphabet, while the dollar took a dive against the yen, which rallied sharply after Japanese wage data upped the chances of another ...

NEW YORK/SINGAPORE (Reuters) -Asia shares rose on Thursday, tracking gains on Wall Street following a see-saw session, while ...

EUROPEAN shares ended Wednesday’s choppy session higher, as a rise in healthcare companies GSK and Novo Nordisk following ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The S&P 500 index provided investors with record gains over the past two years. In 2025, that same approach may not reap the ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...